Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2019

01-08-2019 | Epigenetics | Original Article

H3K9me3, H3K36me3, and H4K20me3 Expression Correlates with Patient Outcome in Esophageal Squamous Cell Carcinoma as Epigenetic Markers

Authors: Menghan Zhou, Yiping Li, Shaofeng Lin, Yanping Chen, Yanyan Qian, Zhujiang Zhao, Hong Fan

Published in: Digestive Diseases and Sciences | Issue 8/2019

Login to get access

Abstract

Background

Histone methylation, as an essential pattern of posttranslational modifications, contributes to multiple cancer-related biological processes. Dysregulation of histone methylation is now considered a biomarker for cancer prognosis.

Aims

This study investigated and evaluated the potential role of four histone lysine trimethylation markers as biomarkers for esophageal squamous cell carcinoma (ESCC) prognosis.

Methods

Tissue arrays were made from 135 paraffin-embedded ESCC samples and examined for histone markers by immunohistochemistry, and 10 pairs of cancer and noncancerous mucosa tissues from ESCC patients were investigated with Western blot. Chi-squared test, Kaplan–Meier analysis with log-rank test, and Cox proportional hazard trend analyses were performed to assess the prognostic values of the markers.

Results

Histone 3 lysine 4 trimethylation (H3K4me3), histone 3 lysine 9 trimethylation (H3K9me3), and histone 4 lysine 20 trimethylation (H4K20me3), but not histone 3 lysine 36 trimethylation (H3K36me3), showed stronger immunostaining signals in tumor tissues than in the corresponding adjacent non-neoplastic mucosa tissues. The expression patterns of H3K36me3, H3K9me3, and H4K20me3 correlated with tumor infiltrating depth, lymph node involvement, and pTNM stage. Low-scoring H3K9me3 and H4K20me3 predicted better prognosis, while H3K36me3 manifested the opposite trend. Poor prognosis occurred in ESCC patients with expression patterns of high levels of H3K9me3, high levels of H4K20me3, and low levels of H3K36me3 expression.

Conclusions

H3K9me3, H4K20me3, and H3K36me3 showed a close relationship with clinical features and were considered independent risk factors for survival of ESCC patients. The combination of H3K9me3, H4K20me3, and H3K36me3 expression, rather than the expression of a single histone marker, is believed to further enhance evaluations of ESCC prognosis and management.
Appendix
Available only for authorised users
Literature
1.
Bernard WS, Christopher PW. World cancer report. Lyon: International Agency for Research on Cancer; 2014.
2.
3.
4.
Katoh H, Qin ZS, Liu R, et al. FOXP3 orchestrates H4K16 acetylation and H3K4 tri-methylation for activation of multiple genes through recruiting MOF and causing displacement of PLU-1. Mol Cell. 2011;44:770–784.CrossRefPubMedPubMedCentral
5.
Zee BM, Levin RS, Xu B, LeRoy G, Wingreen NS, Garcia BA. In vivo residue-specific histone methylation dynamics. J Biol Chem. 2010;285:3341–3350.CrossRefPubMed
6.
Deb M, Kar S, Sengupta D, et al. Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer. Cell Mol Life Sci. 2014;71:3439–3463.CrossRefPubMed
7.
Bernstein BE, Humphrey EL, Erlich RL, et al. Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci USA. 2002;99:8695–8700.CrossRefPubMed
8.
Santos-Rosa H, Schneider R, Bannister AJ, et al. Active genes are tri-methylated at K4 of histone H3. Nature. 2002;419:407–411.CrossRefPubMed
9.
Chen K, Chen Z, Wu D, et al. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nat Genet. 2015;47:1149–1157.CrossRefPubMedPubMedCentral
10.
He C, Xu J, Zhang J, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012;43:1425–1435.CrossRefPubMed
11.
Ellinger J, Kahl P, Mertens C, et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer. 2010;127:2360–2366.CrossRefPubMed
12.
Li GM. Decoding the histone code: role of H3K36me3 in mismatch repair and implications for cancer susceptibility and therapy. Can Res. 2013;73:6379–6383.CrossRef
13.
14.
Schotta G, Lachner M, Sarma K, et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 2004;18:1251–1262.CrossRefPubMedPubMedCentral
15.
Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell. 2007;25:1–14.CrossRefPubMed
16.
Rosenfeld JA, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genom. 2009;10:143.CrossRef
17.
Pauler FM, Sloane MA, Huang R, et al. H3K27me3 forms BLOCs over silent genes and intergenic regions and specifies a histone banding pattern on a mouse autosomal chromosome. Genome Res. 2009;19:221–233.CrossRefPubMedPubMedCentral
18.
Slee RB, Steiner CM, Herbert BS, et al. Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene. 2012;31:3244–3253.CrossRefPubMed
19.
Peters AH, O’Carroll D, Scherthan H, et al. Loss of the Suv39 h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107:323–337.CrossRef
20.
21.
Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer. 2014;14:531.CrossRefPubMedPubMedCentral
22.
Jorgensen S, Schotta G, Sorensen CS. Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Res. 2013;41:2797–2806.CrossRefPubMedPubMedCentral
23.
Ho TH, Kapur P, Joseph RW, et al. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol. 2016;29:34–42.CrossRefPubMed
24.
Munshi A, Shafi G, Aliya N, Jyothy A. Histone modifications dictate specific biological readouts. J Genet Genomics. 2009;36:75–88.CrossRefPubMed
25.
Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48:491–507.CrossRefPubMed
26.
Lehnertz B, Ueda Y, Derijck AA, et al. Suv39 h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol. 2003;13:1192–1200.CrossRefPubMed
27.
28.
Paschall AV, Yang D, Lu C, et al. H3K9 trimethylation silences Fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J Immunol (Baltimore, Md.: 1950). 2015;195:1868–1882.CrossRef
29.
Kylie K, Romero J, Lindamulage IK, Knockleby J, Lee H. Dynamic regulation of histone H3K9 is linked to the switch between replication and transcription at the Dbf4 origin-promoter locus. Cell Cycle (Georgetown, Tex.). 2016;15:2321–2335.CrossRef
30.
Wang DY, An SH, Liu L, et al. Hepatitis B virus X protein influences enrichment profiles of H3K9me3 on promoter regions in human hepatoma cell lines. Oncotarget. 2016;7:84883–84892.PubMedPubMedCentral
31.
Belyaeva A, Venkatachalapathy S, Nagarajan M, Shivashankar GV, Uhler C. Network analysis identifies chromosome intermingling regions as regulatory hotspots for transcription. Proc Natl Acad Sci USA. 2017;114:13714–13719.CrossRefPubMed
32.
Brustel J, Kirstein N, Izard F, et al. Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication. EMBO J. 2017;36:2726–2741.CrossRefPubMedPubMedCentral
33.
Nelson DM, Jaber-Hijazi F, Cole JJ, et al. Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability. Genome Biol. 2016;17:158.CrossRefPubMedPubMedCentral
34.
Vieira FQ, Costa-Pinheiro P, Almeida-Rios D, et al. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets cyclin D2 through H4K20me3. Oncotarget. 2015;6:13644–13657.PubMedPubMedCentral
35.
Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res. 2008;14:7237–7245.CrossRef
36.
Kar S, Patra SK. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression. Gene. 2018;643:35–45.CrossRefPubMed
37.
Santos-Barriopedro I, Bosch-Presegue L, Marazuela-Duque A, et al. SIRT6-dependent cysteine monoubiquitination in the PRE-SET domain of Suv39h1 regulates the NF-κB pathway. Nat Commun. 2018;9:101.CrossRefPubMedPubMedCentral
38.
Keung EZ, Akdemir KC, Al Sannaa GA, et al. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Investig. 2015;125:2965–2978.CrossRefPubMed
39.
Yokoyama Y, Matsumoto A, Hieda M, et al. Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res. 2014;16:R66.CrossRefPubMedPubMedCentral
40.
Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391–400.CrossRefPubMed
41.
42.
Cao F, Fang Y, Tan HK, et al. Super-enhancers and broad H3K4me3 domains form complex gene regulatory circuits involving chromatin interactions. Sci Rep. 2017;7:2186.CrossRefPubMedPubMedCentral
43.
44.
Funata S, Matsusaka K, Yamanaka R, et al. Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget. 2017;8:55265–55279.CrossRefPubMedPubMedCentral
45.
Gu P, Chen X, Xie R, et al. lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 2017;25:1959–1973.CrossRefPubMedPubMedCentral
46.
Zhang Z, Shi L, Dawany N, Kelsen J, Petri MA, Sullivan KE. H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus. Clin Epigenet. 2016;8:14.CrossRef
47.
Keogh MC, Kurdistani SK, Morris SA, et al. Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell. 2005;123:593–605.CrossRefPubMed
48.
Carrozza MJ, Li B, Florens L, et al. Histone H3 methylation by set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell. 2005;123:581–592.CrossRefPubMed
49.
Aymard F, Bugler B, Schmidt CK, et al. Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat Struct Mol Biol. 2014;21:366–374.CrossRefPubMedPubMedCentral
50.
Chantalat S, Depaux A, Hery P, et al. Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin. Genome Res. 2011;21:1426–1437.CrossRefPubMedPubMedCentral
51.
Li J, Moazed D, Gygi SP. Association of the histone methyltransferase set2 with RNA polymerase II plays a role in transcription elongation. J Biol Chem. 2002;277:49383–49388.CrossRefPubMed
52.
Li L, Wang Y. Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair. J Biol Chem. 2017;292:11951–11959.CrossRefPubMedPubMedCentral
53.
Huang Y, Gu L, Li GM. H3K36me3-mediated mismatch repair preferentially protects actively transcribed genes from mutation. J Biol Chem. 2018;293:7811–7823.CrossRefPubMedPubMedCentral
54.
Pfister SX, Markkanen E, Jiang Y, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015;28:557–568.CrossRefPubMedPubMedCentral
55.
Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153:590–600.CrossRefPubMedPubMedCentral
56.
Rogawski DS, Grembecka J, Cierpicki T. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Future Med Chem. 2016;8:1589–1607.CrossRefPubMedPubMedCentral
Metadata
Title
H3K9me3, H3K36me3, and H4K20me3 Expression Correlates with Patient Outcome in Esophageal Squamous Cell Carcinoma as Epigenetic Markers
Authors
Menghan Zhou
Yiping Li
Shaofeng Lin
Yanping Chen
Yanyan Qian
Zhujiang Zhao
Hong Fan
Publication date
01-08-2019
Publisher
Springer US
Keyword
Epigenetics
Published in
Digestive Diseases and Sciences / Issue 8/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05529-2

Other articles of this Issue 8/2019

Digestive Diseases and Sciences 8/2019 Go to the issue

Original Article

Changes in Clock Genes Expression in Esophagus in Rat Reflux Esophagitis

Original Article

Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice

Original Article

Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life

Original Article

Positive Association Between Helicobacter pylori Infection and Metabolic Syndrome in a Korean Population: A Multicenter Nationwide Study

Editorial

Do Vigorous Esophageal Contractions Contribute to Rigorous Phenotyping of Gastroesophageal Reflux Disease?

Original Article

Antibiotics Do Not Decrease the Rate of Infection After Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Cysts

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits